Tyra Biosciences, Inc.
NASDAQ: TYRA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Todd Harris
- Employees
- 60
- Headquarters
- Carlsbad, United States
- IPO year
- 2021
- Market cap
- $1.8B
- Website
- https://www.tyra.bio
Loading TYRA…
Loading profile data…Frequently asked questions about TYRA
What does Tyra Biosciences, Inc. (TYRA) do?
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasiv...
Where does TYRA trade?
Tyra Biosciences, Inc. (TYRA) trades on the NASDAQ Global Select.
What sector is TYRA in?
Tyra Biosciences, Inc. (TYRA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tyra Biosciences, Inc.?
Todd Harris is the chief executive officer of Tyra Biosciences, Inc. (TYRA).
Where is Tyra Biosciences, Inc. headquartered?
Tyra Biosciences, Inc. is headquartered in United States.
Does TYRA pay a dividend?
Tyra Biosciences, Inc. (TYRA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TYRA go public?
Tyra Biosciences, Inc. (TYRA) completed its initial public offering in 2021.